<DOC>
	<DOCNO>NCT01612871</DOCNO>
	<brief_summary>This biomedical prospective study interventional type . The trial include 29 patient period 15 month + 24 month follow maximum . The study conduct womens metastatic invasive breast cancer locally advance breast cancer treatment tamoxifen anti aromatase ( first line hormone therapy metastatic breast cancer ) indicate . The main objective pilot study evaluate feasibility detect circulate blood patient , treatment ( T0 ) , presence fifteen tissular microRNAs describe preclinical study possibly involve hormone resistance/sensitivity . In parallel detection specific miRNAs , conduct large scale analysis circulate miRNAs patient ( T = 0 ) one month treatment ( T28 ) .</brief_summary>
	<brief_title>Circulating miRNAs Biomarkers Hormone Sensitivity Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Women 18 year old ( menopausal ) 2 . Women metastatic invasive breast cancer locally advance ( without surgical project ) , treatment tamoxifen anti aromatase +/ LHRH agonist , indicate ( antiaromatase prescribe menopausal womens ; tamoxifen prescribe menopausal , pre menopausal menopausal womens ) . 3 . Cancer hormoneexpressing estrogen receptor ( ER ) / progesterone receptor ( PR ) ( &gt; = 10 % tumor cell IHC technique ) . Cancer HER2 negative . 4 . Evaluable disease ( measurable accord RECIST criterion ) 5 . Any previous adjuvant hormone therapy discontinue least 21 day . 6 . One two prior metastatic line chemotherapy allow 7 . General status WHO 02 8 . The woman childbearing age must use effective contraception duration study 9 . Informed consent obtain sign specific study procedure 10 . Patient member national insurance scheme 1 . Patient already treat hormone therapy stop previous adjuvant hormone therapy least 21 day . 2 . Prescription chemotherapy / target therapy ( hormone therapy ) treatment breast cancer 3 . Any previous hormone therapy metastatic locally advanced ( without surgical project ) breast cancer 4 . Known hypercalcaemia miRNA dosage T=0 require immediate biphosphonate therapy 5 . Any medical psychiatric condition severe chronic laboratory abnormality make inclusion patient study inappropriate opinion investigator . 6 . Patient unable follow procedure , visit , examination describe study . 7 . Pregnant woman nurse mother participate study . 8 . Patients legal guardianship</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Breast cancer ,</keyword>
	<keyword>hormonotherapy ,</keyword>
	<keyword>miRNAs ,</keyword>
	<keyword>biomarkers</keyword>
	<keyword>hormone therapy</keyword>
</DOC>